Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study
Purpose This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens. Methods A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022. Results The overal...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Journal of the International Association of Providers of AIDS Care |
| Online Access: | https://doi.org/10.1177/23259582241303305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575477399683072 |
|---|---|
| author | Mohammed Jemal MSc Baye Ashenef MSc Deresse Sinamaw MSc Adane Adugna MSc Mamaru Getinet MSc Temesgen Baylie MSc Nuredin Chura Waritu MSc |
| author_facet | Mohammed Jemal MSc Baye Ashenef MSc Deresse Sinamaw MSc Adane Adugna MSc Mamaru Getinet MSc Temesgen Baylie MSc Nuredin Chura Waritu MSc |
| author_sort | Mohammed Jemal MSc |
| collection | DOAJ |
| description | Purpose This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens. Methods A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022. Results The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens ( P = .019). Body mass index ≥ 25 kg/m 2 (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm 3 (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = 2.86; 95% CI: 1.14-7.20) were associated with metabolic syndrome. Conclusion The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome. |
| format | Article |
| id | doaj-art-bf6e2e7bc4354f6c991d90832dbe07c9 |
| institution | Kabale University |
| issn | 2325-9582 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of the International Association of Providers of AIDS Care |
| spelling | doaj-art-bf6e2e7bc4354f6c991d90832dbe07c92025-02-01T06:03:20ZengSAGE PublishingJournal of the International Association of Providers of AIDS Care2325-95822024-12-012310.1177/23259582241303305Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional StudyMohammed Jemal MSc0Baye Ashenef MSc1Deresse Sinamaw MSc2Adane Adugna MSc3Mamaru Getinet MSc4Temesgen Baylie MSc5Nuredin Chura Waritu MSc6 Department of Biomedical Science, School of Medicine, , Debre Markos, Ethiopia Department of Biomedical Science, School of Medicine, , Debre Markos, Ethiopia Department of Biomedical Science, School of Medicine, , Debre Markos, Ethiopia Department of Medical Laboratory Sciences, College of Health Sciences, , Debre Markos, Ethiopia Department of Biomedical Science, School of Medicine, , Debre Markos, Ethiopia Department of Biomedical Science, School of Medicine, , Debre Markos, Ethiopia Department of Biomedical Sciences, School of Medicine, , Wolaita Sodo, EthiopiaPurpose This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens. Methods A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022. Results The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens ( P = .019). Body mass index ≥ 25 kg/m 2 (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm 3 (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = 2.86; 95% CI: 1.14-7.20) were associated with metabolic syndrome. Conclusion The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.https://doi.org/10.1177/23259582241303305 |
| spellingShingle | Mohammed Jemal MSc Baye Ashenef MSc Deresse Sinamaw MSc Adane Adugna MSc Mamaru Getinet MSc Temesgen Baylie MSc Nuredin Chura Waritu MSc Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study Journal of the International Association of Providers of AIDS Care |
| title | Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study |
| title_full | Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study |
| title_fullStr | Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study |
| title_full_unstemmed | Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study |
| title_short | Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study |
| title_sort | metabolic syndrome among people living with hiv on dolutegravir and efavirenz based antiretroviral therapy in ethiopia a comparative cross sectional study |
| url | https://doi.org/10.1177/23259582241303305 |
| work_keys_str_mv | AT mohammedjemalmsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy AT bayeashenefmsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy AT deressesinamawmsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy AT adaneadugnamsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy AT mamarugetinetmsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy AT temesgenbayliemsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy AT nuredinchurawaritumsc metabolicsyndromeamongpeoplelivingwithhivondolutegravirandefavirenzbasedantiretroviraltherapyinethiopiaacomparativecrosssectionalstudy |